Marcelo Garrido
Pontificia Universidad Católica de Chile
H-index: 32
Latin America-Chile
Top articles of Marcelo Garrido
Assessing the Occurrence and Influence of Cancer Chemotherapy-Related Pharmacogenetic Alleles in the Chilean Population
Pharmaceutics
2024/4
Marcelo Garrido
H-Index: 23
Deciphering the genomic landscape of Chilean cancer: Unveiling driver pathway divergence, and novel germline and actionable somatic variants
Cancer Research
2024/3/22
Tumor genomic heterogeneity in non-small cell lung cancer (NSCLC) patients from Latin America
Cancer Research
2024/3/22
Alejandro Blanco
H-Index: 9
Katherine Marcelain
H-Index: 13
Alejandro Corvalan
H-Index: 10
Marcelo Garrido
H-Index: 23
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Journal of Clinical Oncology
2024/2/21
Lin Shen
H-Index: 10
Marcelo Garrido
H-Index: 23
Michalis Karamouzis
H-Index: 21
Rui Wang
H-Index: 3
Ming Lei
H-Index: 2
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant …
2024/1/20
Nivolumab (NIVO)+ chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC …
2024/1/20
Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal …
2024/1/20
Marcelo Garrido
H-Index: 23
KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1 …
2023/6/1
Impact of Adjuvant FOLFOX on Quality of Life and Peripheral Neuropathy Incidence in Patients With Gastric Cancer: A Prospective Cohort Study
Value in Health Regional Issues
2023/5/1
Francisco Acevedo
H-Index: 11
Carlos Balmaceda
H-Index: 6
Marcelo Garrido
H-Index: 23
Bruno Nervi
H-Index: 14
Abstract CT037: Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma …
Cancer Research
2023/4/14
Jin Yao
H-Index: 2
Lin Shen
H-Index: 10
Marcelo Garrido
H-Index: 23
Michalis Karamouzis
H-Index: 21
Ming Lei
H-Index: 2
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
The Lancet Oncology
2023/12/1
Tim Meyer
H-Index: 12
Mariusz Kwiatkowski
H-Index: 5
Jee Hyun Kim
H-Index: 50
Anran Wang
H-Index: 7
William Sievert
H-Index: 33
Jennifer Knox
H-Index: 52
Marcelo Garrido
H-Index: 23
Zhiqiang Meng
H-Index: 5
Xi Chen
H-Index: 13
Tao Zhang
H-Index: 43
Xin Wang
H-Index: 6
Xiaoming Chen
H-Index: 20
Dong Yan
H-Index: 18
Hong Zhao
H-Index: 18
Victor Ramos
H-Index: 2
Thomas Berg
H-Index: 5
Christian Lange
H-Index: 9
Ray Mcdermott
H-Index: 21
Giuseppe Tonini
H-Index: 48
Stefania Gori
H-Index: 35
Tomohiro Arakawa
H-Index: 1
Masahiro Kobayashi
H-Index: 1
Tae-You Kim
H-Index: 10
Han Sang Kim
H-Index: 3
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of …
2023/4/1
129O Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction …
Annals of Oncology
2023/11/1
VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III …
Annals of Oncology
2023/3/1
The Mechanistic Link Between Oral Health and Immune Profile in Gastric Cancer
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
2023/11/1
Marcelo Garrido
H-Index: 23
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC …
2023/2/1
Writing to learn history: intertextuality in secondary school and university students in Chile, Historical Encounters, 10 (1), 144-158
OPEN ACCESS POLICY
2023
Abstract C018: Disparities in the access to non-small cell lung cancer´ s target therapies in Chile
2023/1/1
Alejandro Blanco
H-Index: 9
Marcelo Garrido
H-Index: 23
Gareth Owen
H-Index: 5
Katherine Marcelain
H-Index: 13
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
The Lancet Oncology
2023/11/1
Fernando Rivera
H-Index: 2
Marcelo Garrido
H-Index: 23
Jin Li
H-Index: 20
Rachel Wong
H-Index: 37
Michael Raphael
H-Index: 9
Scott Berry
H-Index: 15
Xiaochun Zhang
H-Index: 6
Xiaoyan Lin
H-Index: 7
Wei Li
H-Index: 8
Xi Chen
H-Index: 13
Lin Yang
H-Index: 51
Lin Zhao
H-Index: 4
Ping Chen
H-Index: 14
Feng Ye
H-Index: 14
Qun Zhao
H-Index: 15
Tomas Svoboda
H-Index: 16
Julio Ramirez
H-Index: 15
Wendy Chan
H-Index: 4
Maeve Lowery
H-Index: 29
Ray Mcdermott
H-Index: 21
Patrick Morris
H-Index: 19
1516P Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro)+ chemotherapy (chemo) for advanced HER2-negative gastric or …
Annals of Oncology
2023/10/1
